Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on ...

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...

The company's stock soared over 177% on Monday to a new 52-week high of $95.77. On the same day, Kodiak reported that the Phase 3 DAYBREAK trial evaluating its lead drug Zenkuda achieved its primary ...

The company saw a 52-week high of $230.49 on Monday.

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction ...

Nautilus Biotechnology, Inc. is currently listed on NASDAQ under NAUT. One share of NAUT stock can currently be purchased for approximately $2.57. Is Nautilus Biotechnology, Inc. listed on the NASDAQ ...